失眠市場規模、佔有率和成長分析：按治療方法、失眠類型、藥物類別、最終用戶、患者群體、分銷管道和地區分類－2026-2033年產業預測

2024 年全球失眠市場價值 48.7 億美元，預計到 2025 年將成長至 51.7 億美元，到 2033 年將成長至 83.7 億美元，在預測期（2026-2033 年）內複合年成長率為 6.2%。

全球失眠市場專注於診斷、治療和管理睡眠障礙的產品，包括藥品、膳食補充劑和穿戴式裝置。失眠與多種慢性疾病、生產力下降以及全球醫療保健成本上升密切相關，凸顯了該市場的重要性。睡眠障礙盛行率的不斷上升是推動市場成長的關鍵因素，而媒體消費的增加以及工作和個人壓力水平的提高往往會加劇這一問題。傳統的治療方法主要以苯二氮平類藥物為主，但目前正轉向更安全的替代療法，例如Orexin拮抗劑、褪黑素和行為療法。市場正在向基於技術的解決方案轉型，包括數位療法和循證的個人化干預措施。與行動應用程式和企業健康計劃的整合正在推動市場擴張，促進非藥物療法的普及，並提高患者自主管理睡眠健康的動機。

全球失眠市場成長要素

民眾和醫療專業人員對睡眠健康的日益重視，促使更多人尋求失眠評估和管理方案，從而擴大了各種治療產品和服務的患者群體。這種意識的提升推動了積極主動的措施，促進了早期診斷，並鼓勵使用實證療法，所有這些都刺激了製藥、醫療設備和行為療法領域的市場需求。此外，醫療機構正在將睡眠評估納入常規體檢，從而製定治療方案，並透過跨學科合作擴大市場准入。

全球失眠市場的限制因素

全球失眠市場面臨許多限制因素，主要原因是不同醫療機構和保險公司對藥物、行為療法和創新療法的保險覆蓋範圍有限。這種缺乏全面保障的情況會導致高額的自付費用，迫使患者依賴非處方藥或乾脆放棄治療，最終抑制了對高品質產品和服務的需求。這些經濟障礙阻礙了市場滲透，抑制了新療法的推廣，並最終影響了失眠行業相關製造商和醫療機構的商機。此外，睡眠相關服務缺乏標準化的編碼也為保險報銷帶來挑戰，進一步阻礙了醫療機構進入該市場。

全球失眠市場趨勢

全球失眠市場正經歷一場重大變革，而推動這項變革的正是數位療法和行動睡眠追蹤技術的興起。這一趨勢的特點是將人工智慧驅動的個人化技術融入認知行為療法，使消費者能夠透過智慧型手機獲得個人化的治療方案。隨著人們對傳統藥物治療的依賴性降低，患者參與度不斷提高，加速了向訂閱式收入模式的轉變。隨著醫療專業人員擴大採用實證數位解決方案，保險公司也開始意識到這些方案的價值，進一步擴大了市場接受度。因此，傳統的助眠產品製造商正尋求與科技公司建立策略合作夥伴關係，以透過零售和企業健康計畫拓展其分銷網路。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球失眠市場規模：依治療類型分類

• 藥物治療
• 認知行為療法
• 醫療器材
• 其他

全球失眠市場規模：以失眠類型分類

• 急性失眠
• 慢性失眠
• 合併失眠症

全球失眠市場規模：依藥物類別分類

• 苯二氮平類藥物
• 雙Orexin受體拮抗劑
• 褪黑素受體促效劑
• 其他

全球失眠市場規模：依最終用戶分類

• 醫院
• 睡眠診所
• 居家照護環境
• 其他

全球失眠市場規模：依病患小組分類

• 成年患者
• 老年患者

全球失眠市場規模：按分銷管道分類

• 醫院藥房
• 零售藥房
• 網路藥房
• 其他

全球失眠市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Eisai Co., Ltd.
• Idorsia Ltd.
• Takeda Pharmaceutical Company Limited
• Merck & Co., Inc.
• Johnson & Johnson
• Pfizer Inc.
• Sanofi SA
• Neurim Pharmaceuticals Ltd.
• Vanda Pharmaceuticals Inc.
• Axsome Therapeutics, Inc.
• Harmony Biosciences Holdings, Inc.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Aurobindo Pharma Limited
• Zydus Lifesciences Limited
• Lupin Limited
• Eli Lilly and Company
• Neurocrine Biosciences, Inc.

結論與建議

Global Insomnia Market size was valued at USD 4.87 Billion in 2024 and is poised to grow from USD 5.17 Billion in 2025 to USD 8.37 Billion by 2033, growing at a CAGR of 6.2% during the forecast period (2026-2033).

The global insomnia market focuses on products that diagnose, treat, and manage sleep disturbances, including medications, supplements, and wearables. Insomnia is linked to various chronic illnesses, reduced productivity, and rising healthcare costs worldwide, which underscores the market's significance. A key driver of growth is the increasing prevalence of sleep disorders, often exacerbated by heightened media consumption and rising stress levels from work and personal life. Traditional treatments, primarily benzodiazepines, are giving way to safer alternatives like orexin antagonists, melatonin, and behavioral therapies. The market is shifting towards technology-based solutions, including digital therapeutics and personalized, evidence-based interventions. The integration of mobile applications and corporate wellness programs is facilitating market expansion, promoting non-medication approaches and enhancing patient engagement in their own sleep health.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Insomnia market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Insomnia Market Segments Analysis

Global insomnia market is segmented by treatment type, insomnia type, drug class, end user, patient group, distribution channel and region. Based on treatment type, the market is segmented into Pharmacological Treatment, Cognitive Behavioral Therapy, Medical Devices and Others. Based on insomnia type, the market is segmented into Acute Insomnia, Chronic Insomnia and Comorbid Insomnia. Based on drug class, the market is segmented into Benzodiazepines, Dual Orexin Receptor Antagonists, Melatonin Receptor Agonists and Others. Based on end user, the market is segmented into Hospitals, Sleep Clinics, Homecare Settings and Others. Based on patient group, the market is segmented into Adult Patients and Geriatric Patients. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Insomnia Market

The increasing recognition of sleep health among the public and healthcare professionals is driving more people to pursue evaluations and management solutions for insomnia, thereby enlarging the patient population for various therapeutic products and services. This growing awareness leads to proactive measures, facilitates early diagnoses, and encourages the use of evidence-based treatments, all of which boost demand across the pharmaceutical, device, and behavioral sectors of the market. Additionally, healthcare providers are incorporating sleep assessments into standard check-ups, which helps normalize treatment methods and expands market access through collaborative efforts among different medical disciplines.

Restraints in the Global Insomnia Market

The global insomnia market faces significant restraints primarily due to limited coverage for medications, behavioral therapies, and innovative treatments by various healthcare providers and insurers. This lack of comprehensive insurance can lead to high out-of-pocket expenses, prompting individuals to rely on over-the-counter remedies or to avoid seeking treatment entirely, which in turn stifles demand for higher-quality products and services. These financial obstacles impede the market's penetration and hinder the acceptance of new interventions, ultimately affecting revenue opportunities for manufacturers and healthcare providers involved in the insomnia industry. Additionally, the absence of standardized coding for sleep services creates challenges in reimbursement, further discouraging provider participation.

Market Trends of the Global Insomnia Market

The global insomnia market is experiencing a significant transformation driven by the rise of digital therapies and mobile sleep-tracking technologies. This trend is characterized by the integration of AI-driven personalization in cognitive-behavioral interventions, enabling consumers to access tailored therapeutic solutions via their smartphones. As reliance on traditional pharmacologic treatments diminishes, engagement levels among patients rise, fostering a shift toward subscription-based revenue models. With growing clinician endorsement of evidence-based digital solutions, insurance providers are beginning to recognize their value, facilitating broader market acceptance. Consequently, traditional sleep aid manufacturers are exploring strategic partnerships with technology firms to expand distribution through retail and corporate wellness avenues.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Insomnia Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Pharmacological Treatment
• Cognitive Behavioral Therapy
• Medical Devices
• Others

Global Insomnia Market Size by Insomnia Type & CAGR (2026-2033)

• Market Overview
• Acute Insomnia
• Chronic Insomnia
• Comorbid Insomnia

Global Insomnia Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Benzodiazepines
• Dual Orexin Receptor Antagonists
• Melatonin Receptor Agonists
• Others

Global Insomnia Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Sleep Clinics
• Homecare Settings
• Others

Global Insomnia Market Size by Patient Group & CAGR (2026-2033)

• Market Overview
• Adult Patients
• Geriatric Patients

Global Insomnia Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Insomnia Market Size & CAGR (2026-2033)

• North America (Treatment Type, Insomnia Type, Drug Class, End User, Patient Group, Distribution Channel)
  • US
  • Canada
• Europe (Treatment Type, Insomnia Type, Drug Class, End User, Patient Group, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Insomnia Type, Drug Class, End User, Patient Group, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Insomnia Type, Drug Class, End User, Patient Group, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Insomnia Type, Drug Class, End User, Patient Group, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Eisai Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Idorsia Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurim Pharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vanda Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Axsome Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Harmony Biosciences Holdings, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurocrine Biosciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations